GMP Compliant Production of Therapeutic Components of Autologous Adipose Tissue.
Uguten M., van Boxtel J., Stevens HP., Harmsen MC., van Dongen JA.
Clinical Trial, published in Methods Mol Biol (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Methods Mol Biol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40208546
- DOI
- 10.1007/978-1-0716-4510-9_24
Abstract (original English)
Adipose tissue is a popular source of tissue for cellular therapy in the field of regenerative medicine. The regenerative potential is often ascribed to the presence of stromal vascular fraction (SVF) containing extracellular matrix and multipotent stromal cells secreting a plethora of growth factors to create a regenerative environment. SVF can be isolated by means of enzymatic or mechanical isolation procedures and expanded in culture or directly used intraoperatively. Depending on the clinical use of SVF, specific regulatory requirements are demanded and might classify SVF as an advanced therapy medicinal product (ATMP). As an ATMP, SVF must be manufactured, processed, and controlled according to good manufacturing practice (GMP) guidelines to ensure safety and quality. Subsequently, the GMP standards require extensive validation, process control, and characterization of SVF. Here we report a GMP-compliant production of clinical grade tissue (tSVF) by means of fractionation of adipose tissue (FAT) procedure. Previous validation studies demonstrated tSVF to be safe and feasible for clinical use intraoperatively according to GMP standards with the appropriate release criteria. The presented procedures can be used as a template for the development of an investigational medicinal product dossier to be enclosed in future clinical trials (Fig. 1).
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.